已经发表的文章：1: （2009年，I期临床研究）Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol. 2009 Oct 1;27(28):4718-26. PMID: 19720910.2: （2009年，综述）ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol. 2009 Jul 30;2:33. PMID: 196429983: （2009年，动物研究，发现还具有抗高血压作用）Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N-(2-fluoro-5- methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther. 2009 Jun;329(3):928-37. 4: （2009年，综述）Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46. PMID: 19455266.5: （2008年，动物实验，与雷帕霉素联合使用抑制肝癌）ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol. 2008 Dec;49(6):985-97. PMID: 18930332.6: （2009年，动物实验，对高血压也有作用）ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol. 2009 Feb;53(2):173-8. PMID: 19188829.6: （2009年，基础研究，对AML抑制作用）Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009 Apr 23;113(17):4052-62. PMID: 19144991.7: （2008年，建立检测方法）Simultaneous determination of a hydrophobic drug candidate and its metabolite in human plasma with salting-out assisted liquid/liquid extraction using a mass spectrometry friendly salt. J Pharm Biomed Anal. 2008 Dec 1;48(4):1243-8. PMID:18926659.9: （2008年，体外研究）In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leuk Res. 2008 Jul;32(7):1091-100. PMID: 18160102.10: （2007年，综述）Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PMID: 18040531.11: （2008年，基础研究，对白血病）Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia. 2008 Jan;22(1):138-46. PMID: 17943175.12: （2007年，综述）Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PMID: 17805439.13: （2007，正式报道靶向药物活性）Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem. 2007 Apr 5;50(7):1584-97. PMID:17343372.14: （2007，正式报道靶向药物活性）ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloidleukemia. Blood. 2007 Apr 15;109(8):3400-8. Epub 2007 Jan 5. PMID:1720905515: （2006年，方法学）A high-throughput liquid chromatography/tandem mass spectrometry method for simultaneous quantification of a hydrophobic drug candidate and its hydrophilic metabolite in human urine with a fully automated liquid/liquid extraction. Rapid Commun Mass Spectrom. 2006;20(22):3456-64. PMID: 17066370.16: （2006年，方法学）A high-throughput, fully automated liquid/liquid extraction liquid chromatography/mass spectrometry method for the quantitation of a new investigational drug ABT-869 and its metabolite A-849529 in human plasma samples. Rapid Commun Mass Spectrom. 2006;20(20):3067-75. PMID: 16969771.17: （2006年，初次报道）Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13. PMID: 16648572.18: （2006年，初次报道抗肿瘤靶向治疗活性）Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006. PMID: 16648571.评论：从2006年报道以来，正式的研究论文一共11篇。文章不多，SCI点数不低，但是看研究方法都很简单。原因很简单——药物很强大，很新，但是研究者很少

尖端研究讲究的就是\"时不我待，抢占先机：，本公司提供大量现货，帮助您在第一时间抢占研究制高点。

目前正在进行的ABT-869的临床实验有，从下列列表可见，目前所有研究实验均没有结果，但是该药的体外研究显示出多靶点抑制活性，并且有强大的肿瘤抑制效应了，故而，其临床结果更值得期待。目前正是投入该药基础研究的最好时机。

Study 1:（转移性结肠癌，招募中） NCT ID: NCT00707889Title: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal CancerRecruitment: RecruitingStudy Results: No Results AvailableConditions: Advanced Colorectal CancerInterventions: Drug: ABT-869|Drug: bevacizumab|Drug: oxaliplatin|Drug: folinic acid|Drug: fluorouracil|Drug: ABT-869Sponsors: Abbott|GenentechGender: BothAge Groups: Adult|SeniorPhases: Phase IIEnrollment: 147Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy StudyOther IDs: M10-300|EudraCT: 2007-007081-38First Received: June 27, 2008Start Date: August 2008Completion Date: Last Updated: October 30, 2009Last Verified: October 2009Acronym: Primary Completion Date: March 2011

Study 2:（转移性乳腺癌，启动未招募） NCT ID: NCT00645177Title: Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast CancerRecruitment: Active, not recruitingStudy Results: No Results AvailableConditions: Metastatic Breast CancerInterventions: Drug: ABT-869|Drug: paclitaxel|Drug: Placebo for ABT-869Sponsors: Abbott|GenentechGender: FemaleAge Groups: Adult|SeniorPhases: Phase IIEnrollment: 102Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Randomized|Double Blind (Subject, Investigator)|Parallel Assignment|Safety/Efficacy StudyOther IDs: M10-265|EudraCT 2007-005949-38First Received: March 24, 2008Start Date: July 2008Completion Date: Last Updated: December 15, 2009Last Verified: December 2009Acronym: Primary Completion Date: June 2010

Study 3:（晚期肝癌，启动未招募） NCT ID: NCT00517920Title: Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)Recruitment: Active, not recruitingStudy Results: No Results AvailableConditions: Advanced Hepatocellular CarcinomaInterventions: Drug: ABT-869Sponsors: Abbott|GenentechGender: BothAge Groups: Adult|SeniorPhases: Phase IIEnrollment: 44Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Safety/Efficacy StudyOther IDs: M06-879First Received: August 16, 2007Start Date: August 2007Completion Date: Last Updated: November 13, 2009Last Verified: November 2009Acronym: Primary Completion Date: December 2009

Study 4:（实体瘤，研究撤销） NCT ID: NCT00754104Title: Study of ABT-869 in Combination With Tarceva in Subjects With Solid TumorsRecruitment: WithdrawnStudy Results: No Results AvailableConditions: Solid TumorsInterventions: Drug: ABT-869|Drug: TarcevaSponsors: Abbott|GenentechGender: BothAge Groups: Adult|SeniorPhases: Phase IEnrollment: 0Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Non-Randomized|Open Label|Single Group Assignment|Pharmacokinetics StudyOther IDs: M10-371First Received: September 15, 2008Start Date: September 2008Completion Date: Last Updated: January 28, 2009Last Verified: January 2009Acronym: Primary Completion Date: December 2008

Study 5:（实体瘤，研究撤销，启动未招募） NCT ID: NCT00718380Title: A Phase 1 Study of ABT-869 in Subjects With Solid TumorsRecruitment: Active, not recruitingStudy Results: No Results AvailableConditions: Solid TumorInterventions: Drug: ABT-869Sponsors: Abbott|Abbott Japan Co.,LtdGender: BothAge Groups: Adult|SeniorPhases: Phase IEnrollment: 18Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Non-Randomized|Open Label|Single Group Assignment|Safety/Efficacy StudyOther IDs: M10-227First Received: July 16, 2008Start Date: September 2008Completion Date: Last Updated: December 15, 2009Last Verified: November 2009Acronym: Primary Completion Date: March 2010

Study 6:（晚期非小细胞肺癌，启动未招募） NCT ID: NCT00517790Title: Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)Recruitment: Active, not recruitingStudy Results: No Results AvailableConditions: Non-small Cell Lung Cancer (NSCLC)Interventions: Drug: ABT-869Sponsors: Abbott|GenentechGender: BothAge Groups: Adult|SeniorPhases: Phase IIEnrollment: 139Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Randomized|Open Label|Uncontrolled|Parallel Assignment|Safety/Efficacy StudyOther IDs: M06-880First Received: August 16, 2007Start Date: August 2007Completion Date: Last Updated: November 11, 2009Last Verified: October 2009Acronym: Primary Completion Date: December 2009

Study 7:（转移性非小细胞肺癌，招募中） NCT ID: NCT00716534Title: Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Recruitment: RecruitingStudy Results: No Results AvailableConditions: Advanced or Metastatic Non-Small Cell Lung CancerInterventions: Drug: ABT-869|Drug: PlaceboSponsors: Abbott|GenentechGender: BothAge Groups: Adult|SeniorPhases: Phase IIEnrollment: 120Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Randomized|Double Blind (Subject, Investigator)|Single Group AssignmentOther IDs: M10-301First Received: July 14, 2008Start Date: June 2008Completion Date: Last Updated: November 12, 2009Last Verified: October 2009Acronym: Primary Completion Date: March 2011

Study 8:（晚期肾癌，启动未招募） NCT ID: NCT00486538Title: Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With SunitinibRecruitment: Active, not recruitingStudy Results: No Results AvailableConditions: Advanced Renal Cell CarcinomaInterventions: Drug: ABT-869Sponsors: Abbott|GenentechGender: BothAge Groups: Adult|SeniorPhases: Phase IIEnrollment: 53Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group AssignmentOther IDs: M06-882First Received: June 12, 2007Start Date: August 2007Completion Date: Last Updated: November 30, 2009Last Verified: November 2009Acronym: Primary Completion Date: December 2009

Study 9: （晚期实体瘤，药代动力学研究，招募中） NCT ID: NCT00733187Title: Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869Recruitment: RecruitingStudy Results: No Results AvailableConditions: Advanced or Metastatic Solid TumorsInterventions: Drug: ABT-869Sponsors: Abbott|GenentechGender: BothAge Groups: Adult|SeniorPhases: Phase IEnrollment: 12Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Basic Science|Randomized|Open Label|Crossover Assignment|Pharmacokinetics StudyOther IDs: M10-384First Received: August 8, 2008Start Date: February 2009Completion Date: Last Updated: November 13, 2009Last Verified: November 2009Acronym: Primary Completion Date: December 2009

Study 10:（晚期肝癌，有效性和耐受性，招募中） NCT ID: NCT01009593Title: Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)Recruitment: RecruitingStudy Results: No Results AvailableConditions: Carcinoma, Hepatocellular|Liver Diseases|Neoplasms by Histologic Type|Digestive System Neoplasms|Carcinoma|Liver Neoplasms|Neoplasms|Neoplasms by Site|Digestive System Diseases|Adenocarcinoma|Neoplasms, Glandular and EpithelialInterventions: Drug: ABT-869|Drug: SorafenibSponsors: Abbott|GenentechGender: BothAge Groups: Adult|SeniorPhases: Phase IIIEnrollment: 900Funded Bys: INDUSTRYStudy Types: InterventionalStudy Designs: Treatment|Randomized|Open Label|Parallel AssignmentOther IDs: M10-963First Received: October 14, 2009Start Date: October 2009Completion Date: Last Updated: November 23, 2009Last Verified: November 2009Acronym: Primary Completion Date: February 2012